Dr. Bunn on Data With Trastuzumab Deruxtecan in HER2-Mutant NSCLC

Paul A. Bunn, Jr, MD, highlights encouraging data with fam-trastuzumab deruxtecan-nxki in HER2-mutant non–small cell lung cancer.

Paul A. Bunn, Jr, MD, distinguished professor, James Dudley Chair in Lung Cancer Research, Division of Medical Oncology, University of Colorado Denver, and a 2014 Giant of Cancer Care® in Lung Cancer, highlights encouraging data with fam-trastuzumab deruxtecan-nxki (Enhertu) in HER2-mutant non–small cell lung cancer (NSCLC). 

Results from the phase 2 DESTINY-Lung01 trial (NCT03505710) showed encouraging data with the novel antibody-drug conjugate (ADC), trastuzumab deruxtecan in patients with HER2-mutant NSCLC. The ADC demonstrated high objective response rates and prolongedprogression-free survival, similar to TKIs, says Bunn. The hope is that the agent will be approved in the near future for these patients, adds Bunn.

However, since this ADC is comprised of 3 components, the adverse effects (AEs) are much higher than they are with TKIs.